CSIMarket
 


Adma Biologics Inc   (ADMA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ADMA's Revenue Growth by Quarter and Year

Adma Biologics Inc 's Revenue results by quarter and year




ADMA Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - 12.04 4.06 12.00
III Quarter September - 7.22 4.23 4.73
II Quarter June - 6.56 4.66 3.40
I Quarter March 10.20 3.53 4.04 2.63
FY   10.20 29.35 16.99 22.76



ADMA Revenue first quarter 2020 Y/Y Growth Comment
Adma Biologics Inc achieved in the first quarter, above Company average Revenue surge of 188.94% year on year, to $ 10.20 millions.

Looking into first quarter results within Biotechnology & Drugs industry 2 other companies have achieved higher Revenue growth. While Adma Biologics Inc ' s Revenue doubling of 188.94% ranks overall at the positon no. 18 in the first quarter.




ADMA Revenue ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - 196.55 % -66.17 % 260.36 %
III Quarter September - 70.69 % -10.57 % 60.88 %
II Quarter June - 40.77 % 37.06 % 49.78 %
I Quarter March 188.94 % -12.62 % 53.61 % 24.06 %
FY   - 72.75 % -25.35 % 113.51 %

Financial Statements
Adma Biologics Inc 's first quarter 2020 Revenue $ 10.20 millions ADMA's Income Statement
Adma Biologics Inc 's first quarter 2019 Revenue $ 3.53 millions Quarterly ADMA's Income Statement
New: More ADMA's historic Revenue Growth >>


ADMA Revenue (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - 66.76 % -4.02 % 153.7 %
III Quarter September - 10.06 % -9.23 % 39.12 %
II Quarter June - 85.84 % 15.35 % 29.28 %
I Quarter March -15.28 % -13.05 % -66.33 % -21.02 %
FY (Year on Year)   - 72.75 % -25.35 % 113.51 %




Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #3
Healthcare Sector #9
Overall #18

Revenue Y/Y Growth Statistics
High Average Low
97.33 % 13.31 % -31.87 %
(March 31, 2014)   (Dec 31 2018)
Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #3
Healthcare Sector #9
Overall #18
Revenue Y/Y Growth Statistics
High Average Low
97.33 % 13.31 % -31.87 %
(March 31, 2014)   (Dec 31 2018)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Adma Biologics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
5129.45 % 206.93 % -66.32 %
(Jun 30 2012)  


ADMA's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Adma Biologics Inc realized fall in Revenue sequentially by -15.28% to $ 10.20 millions, from $ 12.04 millions declared in the previous reporting period.

It's not huge problem, as I. Quarter Revenue frequently tend to slow in the I. Quarter Aaron Wolfe, a business researcher allocated in Houston wrote.

Within Biotechnology & Drugs industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Adma Biologics Inc 's Revenue growth quarter on quarter, overall rank is 814.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #12
Healthcare Sector #94
Overall #814
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #12
Healthcare Sector #94
Overall #814
Revenue Q/Q Growth Statistics
High Average Low
5129.45 % 206.93 % -66.32 %
(Jun 30 2012)  


ADMA's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Adma Biologics Inc realized fall in Revenue from the forth quarter by -15.28% to $ 10.20 millions, from $ 12.04 millions achived in the previous qaurter.

When you look into present slump at the I. Quarter, you should assume, that usually I. Quarter Revenue emerge softer then in the forth quarter

Within Biotechnology & Drugs industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Adma Biologics Inc 's Revenue growth quarter on quarter, overall rank is 814.


Adma Biologics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
Cumulative Revenue 12 Months Ending $ 36.02 $ 29.35 $ 21.37 $ 18.38 $ 16.47
Y / Y Revenue Growth (TTM) 118.68 % 72.79 % -14.29 % -27.74 % -31.86 %
Year on Year Revenue Growth Overall Ranking # 110 # 219 # 2677 # 2982 # 3217
Seqeuential Revenue Change (TTM) 22.73 % 37.35 % 16.28 % 11.56 % -3.02 %
Seq. Revenue Growth (TTM) Overall Ranking # 118 # 163 # 273 # 395 # 2947




Cumulative Revenue growth Comment
Adma Biologics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 118.68% year on year, to $ 36 millions if the fiscal year would have ended in Mar 31 2020.
Adma Biologics Inc 's trailing twelve months Revenue growth was higher than company's average 83.11% and higher than 72.79% growth in Dec 31 2019.
But sequential growth rate was beneth at 22.73 % from $29.35 millions reported in the period from Dec 31 2019 to Mar 31 2019 Aaron Wolfe went on.
Still it was confirmation of convincing trend, as the usual sequential growth stands at 13.31%.
The momentum was much more impressive from twelve months ended Dec 31 2019 exhibited at 22.73 % rise from $29.35 millions in twelve months ending a quarter Dec 31 2019.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 110, from total ranking in previous quarter at 219.

Revenue TTM Q/Q Growth Statistics
High Average Low
97.33 %
13.31 %
-31.87 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 16
Healthcare Sector # 39
Overall # 110

Revenue TTM Y/Y Growth Statistics
High Average Low
467.81 %
83.11 %
-31.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 42
S&P 500 # 118
Cumulative Revenue growth Comment
Adma Biologics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 118.68% year on year, to $ 36 millions if the fiscal year would have ended in Mar 31 2020.
Adma Biologics Inc 's trailing twelve months Revenue growth was higher than company's average 83.11% and higher than 72.79% growth in Dec 31 2019.
But from twelve months ended Dec 31 2019 rise was slower at 22.73 % from $29.35 millions reported in twelve months ending a quarter Dec 31 2019 Aaron Wolfe went on.
Yet this was validation of convincing trend, while the average sequential advancement lays at 13.31%.
The progress was even more impressive from the previous reporting period clinched at 22.73 % increase from $29.35 millions in twelve months ending a quarter before.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 110, from total ranking in previous quarter at 219.

Revenue TTM Q/Q Growth Statistics
High Average Low
97.33 %
13.31 %
-31.87 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 16
Healthcare Sector # 39
Overall # 110

Revenue TTM Y/Y Growth Statistics
High Average Low
467.81 %
83.11 %
-31.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 42
S&P 500 # 118




Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADMA's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ADMA's Competitors
Revenue Growth for Adma Biologics Inc 's Suppliers
Revenue Growth for ADMA's Customers

You may also want to know
ADMA's Annual Growth Rates ADMA's Profitability Ratios ADMA's Asset Turnover Ratio ADMA's Dividend Growth
ADMA's Roe ADMA's Valuation Ratios ADMA's Financial Strength Ratios ADMA's Dividend Payout Ratio
ADMA's Roa ADMA's Inventory Turnover Ratio ADMA's Growth Rates ADMA's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2020
Nantkwest Inc   320.00 %$ 320.000 millions
Option Care Health Inc   294.20 %$ 294.197 millions
Cure Pharmaceutical Holding Corp   275.84 %$ 275.839 millions
Amarillo Biosciences Inc  272.91 %$ 272.915 millions
Eyepoint Pharmaceuticals Inc   272.22 %$ 272.217 millions
Theravance Biopharma inc   272.09 %$ 272.087 millions
American Cryostem Corp  264.03 %$ 264.034 millions
Aduro Biotech Inc   254.24 %$ 254.241 millions
Voyager Therapeutics Inc   247.64 %$ 247.643 millions
Aytu Bioscience Inc  243.01 %$ 243.015 millions
Coherus Biosciences inc   213.17 %$ 213.171 millions
Therapeuticsmd Inc   210.41 %$ 210.406 millions
Harpoon Therapeutics Inc   210.16 %$ 210.160 millions
Gw Pharmaceuticals Plc  207.37 %$ 207.369 millions
Zyla Life Sciences  204.52 %$ 204.520 millions
Verastem Inc   202.57 %$ 202.573 millions
Alnylam Pharmaceuticals Inc   198.78 %$ 198.781 millions
Adma Biologics Inc   189.06 %$ 189.060 millions
Agios Pharmaceuticals Inc   188.15 %$ 188.146 millions
Healthlynked Corp  187.52 %$ 187.520 millions
Editas Medicine inc   176.61 %$ 176.607 millions
Checkpoint Therapeutics Inc   176.14 %$ 176.136 millions
Albireo Pharma Inc   171.75 %$ 171.754 millions
Venus Concept Inc   168.97 %$ 168.966 millions
Surface Oncology Inc   167.37 %$ 167.369 millions
Inspiremd Inc   149.16 %$ 149.157 millions
Cue Biopharma Inc   143.24 %$ 143.243 millions
Seneca Biopharma Inc   140.80 %$ 140.800 millions
Catalyst Pharmaceuticals Inc   134.06 %$ 134.057 millions
Protagonist Therapeutics Inc   133.78 %$ 133.782 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

FEPI's Profile

Stock Price

FEPI's Financials

Business Description

Fundamentals

Charts & Quotes

FEPI's News

Suppliers

FEPI's Competitors

Customers & Markets

Economic Indicators

FEPI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071